Sustained Immunological Responses to Highly Active Antiretroviral Therapy at 36 Months in a Ghanaian HIV Cohort

被引：14

作者：

Collini, Paul ^{[1
,5
,6
]}

Schwab, Uli ^{[2
,5
,6
]}

Sarfo, Stephen ^{[5
,6
]}

Obeng-Baah, Joseph ^{[5
,6
]}

Norman, Betty ^{[5
,6
]}

Chadwick, David ^{[3
]}

Bibby, David ^{[4
]}

Bedu-Addo, George ^{[5
,6
]}

机构：

[1] Univ Sheffield, Sch Med & Biomed Sci, Sheffield S10 2RX, S Yorkshire, England

[2] Newcastle Gen Hosp, Dept Infect Dis & Trop Med, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England

[3] James Cook Univ Hosp, Dept Infect & Travel Med, Middlesbrough, Cleveland, England

[4] Barts & London Hosp, Dept Virol, London, England

[5] Komfo Anokye Teaching Hosp, Dept Med, Kumasi, Ghana

[6] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, Ghana

来源：

CLINICAL INFECTIOUS DISEASES | 2009年 / 48卷 / 07期

关键词：

RESOURCE-LIMITED SETTINGS; CD4 CELL COUNT; OUTCOMES; AFRICA;

D O I：

10.1086/597353

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Two hundred thirty-seven Ghanaian human immunodeficiency virus-infected patients who were starting antiretroviral therapy underwent clinical and immunological monitoring for 3 years. Seventy-eight percent of patients had disease classified as World Health Organization stage III or IV. The mean increase in the CD4 cell count was 395 cells/mm(3), 13% of patients experienced immunological failure, and 8% of patients switched treatment to a second-line regimen. However, two-thirds of patients who experienced immunological failure did not switch treatment, and 31% of all patients were lost to follow-up.

引用

页码：988 / 991

页数：4

共 12 条

[1] [Anonymous], 2006, ANT THER HIV INF AD
[2] Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
Bagchi, Shashwatee
Kempf, Mirjam C.
Westfall, Andrew O.
Maherya, Anastasiya
Willig, James
Saag, Michael S.
[J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) : 135 - 138
[3] BASENERO A, 2007, 4 INT AIDS SOC C HIV
[4] Coutinho A, 2008, 15 C RETR OPP INF BO
[5] *GHAN HLTH SERV, 2003, HIV SENT SURV REP 20
[6] *GHAN HLTH SERV, 2003, GUID US ANT THER ACC
[7] Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events
Hoffmann, Christopher J.
Fielding, Katherine L.
Charalambous, Salome
Sulkowski, Mark S.
Innes, Craig
Thio, Chloe L.
Chaisson, Richard E.
Churchyard, Gavin J.
Grant, Alison D.
[J]. AIDS, 2008, 22 (01) : 67 - 74
[8] HOSSEINIPOUR M, 2007, 4 INT AIDS SOC C HIV
[9] CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa
Lawn, SD
Myer, L
Bekker, LG
Wood, R
[J]. BMC INFECTIOUS DISEASES, 2006, 6 (1)
[10] May M, 2007, AIDS, V21, P1185, DOI 10.1097/QAD.0b013e328133f285

← 1 2 →